Printer Friendly

Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate Iomab-B.

M2 PHARMA-October 19, 2016-Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate Iomab-B

(C)2016 M2 COMMUNICATIONS

Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Tuesday the receipt of the orphan designation in the European Union (EU) from the European Medicines Agency (EMA) for its lead asset, Iomab-B.

Upon EMA approval, Iomab-B is intended to be used in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55 for a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT), according to the company.

Currently, Iomab-B is in a 150 patient multicentre, pivotal Phase 3 trial that is being conducted in the US, added the company.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin lymphomas and multiple myeloma, revealed the company.

The EMA grants orphan designation to rare diseases that are defined as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. It is expected to provide increased communication and guidance from regulators and ten year market exclusivity should marketing authorisation be obtained

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 19, 2016
Words:258
Previous Article:Cytokinetics enrols first ALS patient under pen-label extension clinical trial of tirasemtiv.
Next Article:St. Jude Medical Forms Cyber Security Medical Advisory Board.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters